12 July 2018Americas

LSIPR 50 2018: Leading the transformation change

Charged with protecting the innovation arising from MedImmune, the global biologics research and development arm of AstraZeneca, as well as AstraZeneca’s innovative medicines and early development biotech units, Scott Alban’s job is far from insignificant.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Fed Circ orders Teva to delist five patents from Orange Book

Sarepta wins $115M in patent dispute over muscular dystrophy drug

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York

LSIPR 50 2018: Leading the transformation change

Editor's picks

Editor's picks

More features